We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
This correspondence outlines real-world COVID-19 vaccination efficacy in heathcare workers at the University of California, San Diego (UCSD), and the University of California, Los Angeles (UCLA), all of whom had received either the BNT162b2 vaccine or the mRNA-1273 vaccine and were undergoing routine, weekly screening for asymptomatic COVID-19. After vaccination, the absolute risk of testing positive for SARS-CoV-2 was 1.19% and 0.97% among this population of healthcare workers at UCSD and UCLA, respectively. A positive test result 15 days or more after administration of the second dose of vaccine was very rare (7/4167).
Although these rates were higher than in published trials, the absolute risks were low. These data suggest durable efficacy of COVID-19 vaccines outside a trial setting and are very encouraging.
This abstract is available on the publisher's site.
Data from phase 3 clinical trials of messenger RNA (mRNA) vaccines through No-vember 2020 showed 94.1% efficacy for the prevention of symptomatic severe acute respira-tory syndrome coronavirus 2 (SARS-CoV-2) in-fection at 14 days after the second dose of the mRNA-1273 vaccine (Moderna)1 and 95% efficacy at 7 days after the second dose of the BNT162b2 vaccine (Pf izer).2 Since the results of these trials were published, a nationwide surge in coronavirus disease 2019 (Covid-19) has been noted, SARS-CoV-2 variants with increased infectivity have emerged, the Food and Drug Administration has granted emergency use authorization for these two mRNA vaccines, and vaccination has been initiated across the United States